Lifetime alcohol intake is associated with an increased risk of KRAS+ and BRAF‐/KRAS‐ but not BRAF+ colorectal cancer
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30568
Abstract: Ethanol in alcoholic beverages is a causative agent for colorectal cancer. Colorectal cancer is a biologically heterogeneous disease, and molecular subtypes defined by the presence of somatic mutations in BRAF and KRAS are known to… read more here.
Keywords: cancer; kras braf; colorectal cancer; alcohol intake ... See more keywords
Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c01454
Abstract: AKT is an important target for cancer therapeutics. Significant advancements have been made in developing ATP-competitive and allosteric AKT inhibitors. Recently, several AKT proteolysis targeting chimeras (PROTACs) derived from ATP-competitive AKT inhibitors have been reported,… read more here.
Keywords: kras braf; akt proteolysis; proteolysis targeting; akt ... See more keywords
No Tissue Expression of KRAS or BRAF Mutations in 61 Adult Patients Treated for Esophageal Atresia in Early Childhood
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Pediatric Surgery"
DOI: 10.1055/s-0037-1605346
Abstract: Background Previous studies have reported an association among esophageal atresia (EA), Barrett's esophagus, and esophageal adenocarcinoma later in life. Objective The objective of the article is to evaluate KRAS and BRAF mutations as potential genetic… read more here.
Keywords: kras braf; expression kras; tissue expression; braf mutations ... See more keywords
Evaluating whether KRAS/BRAF mutation status, anaemia and obstruction are associated with recurrence and mortality in non-metastatic colorectal cancer.
Sign Up to like & getrecommendations! Published in 2023 at "ANZ journal of surgery"
DOI: 10.1111/ans.18470
Abstract: BACKGROUND KRAS and BRAF testing is currently recommended in metastatic colorectal cancer. There is evidence that KRAS and BRAF mutation status may act as a prognostic biomarker in patients with non-metastatic colorectal cancer. Data is… read more here.
Keywords: kras braf; status; mortality; recurrence ... See more keywords
Impact of KRAS and BRAF mutations on treatment efficacy and survival in high‐grade gastroenteropancreatic neuroendocrine neoplasms
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Neuroendocrinology"
DOI: 10.1111/jne.13256
Abstract: High‐grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP‐NEN) typically disseminate early. Treatment of metastatic disease has limited benefit and prognosis is generally discouraging. Data on the clinical impact of mutations in HG GEP‐NEN are scarce. There is… read more here.
Keywords: kras braf; colon nec; impact; first line ... See more keywords
Abstract 5740: PD-L1 overexpression induced by oncogenic KRAS and BRAF mutations through MAPK pathway activation in non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-5740
Abstract: Mutant KRAS and BRAF are important oncogenic drivers in non-small cell lung cancer (NSCLC), however, effective treatment strategies for most of these mutants have not been established. Immuno-oncology clinical trials have shown promising results of… read more here.
Keywords: kras braf; overexpression; expression; non small ... See more keywords
The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study
Sign Up to like & getrecommendations! Published in 2022 at "Oncology"
DOI: 10.1159/000527285
Abstract: Introduction: KRAS, BRAF, and DNA mismatch repair (MMR) mutations aid clinical decision-making for colorectal cancer (CRC) patients. To ensure accurate predictions, the prognostic utilities of these biomarkers and their combinations must be individualized for patients… read more here.
Keywords: kras braf; mismatch repair; dna mismatch; prognostic utilities ... See more keywords
Predictive Biomarkers of Response to Venetoclax in Combination with Cobimetinib in Relapsed/Refractory Multiple Myeloma (RRMM)
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-134910
Abstract: Introduction: Both anti-apoptosis and pro-survival mechanisms promote myeloma cell growth and proliferation, and B-cell lymphoma-2 (BCL-2) is over-expressed in a subset of myeloma patients (pts). Venetoclax (V; orally administered BCL-2 inhibitor) monotherapy has demonstrated efficacy… read more here.
Keywords: kras braf; combination; nras kras; response ... See more keywords
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Diagnostic Pathology"
DOI: 10.1186/s13000-020-01045-4
Abstract: Background Esophageal squamous cell carcinoma (ESCC) still remains intractable disease with few therapeutic options. Programmed death-ligand 1 (PD-L1), which is essential for immune evasion, is involved in the pathogenesis of ESCC and thus is a… read more here.
Keywords: kras braf; msi; pik3ca mutation; hpv ... See more keywords
Concomitant KRAS and BRAF mutations in colorectal cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of gastrointestinal oncology"
DOI: 10.21037/jgo.2019.01.10
Abstract: BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAP-kinase signaling pathway. While previously considered mutually exclusive, concomitant mutations in both KRAS and BRAF genes have been identified in colorectal cancer (CRC). The clinical outcome… read more here.
Keywords: colorectal cancer; concomitant kras; kras braf; braf mutations ... See more keywords
MicroRNA Expression in KRAS- and BRAF-mutated Colorectal Cancers.
Sign Up to like & getrecommendations! Published in 2018 at "Anticancer research"
DOI: 10.21873/anticanres.12272
Abstract: BACKGROUND/AIM KRAS and BRAF are two genes commonly mutated in colorectal cancer (CRC). Even though BRAF is a downstream target of KRAS in the MAPK signalling pathway, KRAS- and BRAF-mutated CRCs are found to display… read more here.
Keywords: kras braf; mir; braf mutated; mutated colorectal ... See more keywords